Updated:
CNS Pharmaceuticals
CNS Pharmaceuticals, led by CEO John Climaco, is a Houston-based clinical-stage biotech developing Berubicin for brain cancer treatment.
CNS Pharmaceuticals
CNS Pharmaceuticals was founded in 2017 and is headquartered in Houston, Texas. John Climaco serves as CEO, steering a company that does not generate revenue but allocates raised capital entirely into drug development. The business is registered as a public reporting company, and its existence is tied to the performance of a single therapeutic program. The company's sole asset is Berubicin, a novel anthracycline chemotherapy that crosses the blood-brain barrier — a mechanism that has confounded oncology drug developers for decades. CNS in-licensed the compound from Reata Pharmaceuticals and is pursuing it for glioblastoma multiforme, an aggressive brain cancer with a median survival of approximately 15 months. The firm's entire deployment strategy rests on a single ongoing global adaptive trial, evaluating Berubicin against standard-of-care lomustine. The study design adapts dynamically to patient responses, reflecting a deliberate capital conservation strategy where a failed interim analysis halts all cash burn. The firm operates with minimal reported overhead and outsources clinical operations to contract research organizations. It trades on the Nasdaq under ticker CNSP, maintaining a public vehicle structure despite its micro-cap scale. In May 2024 the company executed a 1-for-50 reverse stock split to regain Nasdaq listing compliance, signaling acute balance-sheet pressure. Management has historically funded operations through at-the-market equity offerings and registered direct placements, leaving no meaningful institutional investor concentration. The structural differentiator is not technological but pharmacological: Berubicin is a structurally modified doxorubicin designed to evade multi-drug resistance pumps that block most chemotherapies from entering the central nervous system. No other anthracycline has demonstrated this capability in clinical trials, making the firm a high-leverage binary bet on an unproven mechanism. The entire enterprise depends on a single data readout — a governance structure that aligns all stakeholders behind one scientific question.
General information
Firm type
Asset Manager
Year founded
2017
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Houston
Corporate office
Houston, TX, United States
Principals
John Climaco
Chief Executive Officer
Sector focus
Frequently asked questions
What is CNS Pharmaceuticals' primary drug candidate and how does it work?
Berubicin is an anthracycline chemotherapy analog designed to cross the blood-brain barrier, targeting glioblastoma multiforme. It was in-licensed from Reata Pharmaceuticals and is structured to evade P-glycoprotein efflux pumps that normally prevent chemotherapies from reaching brain tumors. The mechanism relies on a molecular modification to the doxorubicin backbone that allows it to accumulate in the central nervous system.
Does CNS Pharmaceuticals have any other drug candidates beyond Berubicin?
No. The company's pipeline consists of a single asset. All resources are allocated to the ongoing adaptive clinical trial for Berubicin, and there are no disclosed preclinical programs, backup candidates, or discovery-stage assets. This makes CNS a single-program bet on glioblastoma therapy.
How is CNS Pharmaceuticals funded given it has no approved products?
The company funds operations entirely through equity sales, including at-the-market offerings and registered direct placements. It does not have debt facilities, grant funding from foundations, or partnership revenue. Cash runway depends on the pace and pricing of periodic stock issuances, which creates dilution risk for existing shareholders.
What stage is the Berubicin clinical trial currently in?
Berubicin is in a potentially pivotal Phase 2 adaptive trial that compares it against lomustine in recurrent glioblastoma patients. The study is global, with sites in the U.S., Italy, France, Spain, and Switzerland, and uses an adaptive design that can stop early for futility or adjust randomization based on interim results. The trial completed target patient enrollment as of mid-2024.
Who runs investment decisions at CNS Pharmaceuticals?
John Climaco, as CEO, controls the capital allocation function by setting clinical priorities and approving all financings. There is no separate CIO or investment committee structure — resource deployment is synonymous with the clinical development plan for Berubicin, which the CEO and Chief Medical Officer jointly oversee.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: